VYNE Therapeutics Inc. (VYNE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, VYNE Therapeutics reported revenue of $570,000, up 13.8% from $501,000 the year before. Net income was -$26.5M (a -4646.1% net margin), or -$31.00 per diluted share. Operating margin was -5219.1%. Operating activities generated -$33.1M of cash, leaving -$33.1M of free cash flow. At fiscal year end, VYNE Therapeutics held $30.2M in total assets against $2.4M in total liabilities, including $24.0M of cash and equivalents.
Open the full interactive VYNE Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
VYNE Therapeutics Key Stats
| Share Price | $18.60 |
|---|---|
| Market Cap | $16.0M |
| Revenue YoY Growth | +13.8% |
| 52-Week Range | $9.26 – $42.94 |
| Shares Outstanding | 858,000 (basic, 2026 Q2) |
VYNE Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $21.0M | $14.8M | $477,000 | $424,000 | $501,000 | $570,000 |
| Cost of Goods Sold | $1.4M | $3.3M | — | — | — | — |
| Gross Profit | $19.6M | $11.4M | — | — | — | — |
| Operating Income | -$252.5M | -$68.0M | -$34.3M | -$29.3M | -$43.6M | -$29.7M |
| Pre-Tax Income | -$255.8M | -$73.8M | -$33.9M | -$27.9M | -$39.8M | -$26.7M |
| Income Tax | -$258,000 | -$448,000 | $13,000 | $0 | $4,000 | $4,000 |
| Net Income | -$255.6M | -$73.3M | -$23.2M | -$28.5M | -$39.8M | -$26.5M |
| Diluted EPS | -$7095.17 | $1278.00 | -$364.00 | -$139.00 | -$46.50 | -$31.00 |
VYNE Therapeutics Quarterly Results
| 2025 Q1 | 2025 Q2 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $202,000 | $69,000 | $86,000 | $97,000 |
| Net Income | -$8.6M | -$5.8M | -$3.6M | -$3.0M |
| Diluted EPS | -$10.00 | -$6.50 | -$4.00 | -$3.51 |
VYNE Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $57.6M | $42.2M | $30.9M | $30.6M | $19.9M | $24.0M |
| Current Assets | $87.3M | $63.2M | $38.3M | $96.0M | $64.4M | $30.0M |
| Total Assets | $93.7M | $67.0M | $40.8M | $97.7M | $66.9M | $30.2M |
| Current Liabilities | $21.5M | $18.4M | — | $7.5M | $14.8M | $2.4M |
| Total Long-Term Debt | $33.2M | — | — | — | — | — |
| Total Liabilities | $56.2M | $18.4M | $9.3M | $8.9M | $14.8M | $2.4M |
| Shareholders' Equity | $37.5M | $48.6M | $31.2M | $88.7M | $52.1M | $27.8M |
VYNE Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$137.1M | -$56.4M | -$29.2M | -$25.3M | -$34.0M | -$33.1M |
| Cash From Investing | $89.1M | $1.0M | $15.7M | -$57.4M | $23.4M | $37.4M |
| Cash From Financing | $61.8M | $39.8M | $1.7M | $82.4M | -$141,000 | -$143,000 |
| Free Cash Flow | -$137.2M | -$56.4M | — | -$25.3M | -$34.0M | -$33.1M |
Figures from VYNE Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full VYNE Therapeutics financials page for every line item.
VYNE Therapeutics Company Profile
| Ticker | VYNE |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New Haven, Connecticut |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001566044 |
Frequently Asked Questions
What was VYNE Therapeutics' revenue in fiscal 2025?
VYNE Therapeutics (VYNE) reported revenue of $570,000 for fiscal 2025.
What is VYNE Therapeutics' annual revenue history?
VYNE Therapeutics' annual revenue by fiscal year: 2020: $21.0M; 2021: $14.8M; 2022: $477,000; 2023: $424,000; 2024: $501,000; 2025: $570,000.
What was VYNE Therapeutics' net income in fiscal 2025?
VYNE Therapeutics reported net income of -$26.5M for fiscal 2025.
What was VYNE Therapeutics' earnings per share (EPS) in fiscal 2025?
VYNE Therapeutics' diluted EPS was -$31.00 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did VYNE Therapeutics generate in fiscal 2025?
VYNE Therapeutics generated -$33.1M of free cash flow in fiscal 2025.
What was VYNE Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), VYNE Therapeutics reported revenue of $97,000.
How many shares of VYNE Therapeutics are outstanding?
VYNE Therapeutics reported a weighted average of 858,000 basic shares outstanding in 2026 Q2.
What is VYNE Therapeutics' market cap?
Based on its latest closing price, VYNE Therapeutics (VYNE) has a market capitalization of about $16.0M.
When does VYNE Therapeutics' fiscal year end?
VYNE Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is VYNE Therapeutics headquartered?
VYNE Therapeutics lists its business address in New Haven, Connecticut in its SEC filings.